US Stock Insider Trading | Zevra disclosed 5 insider transactions on February 2

K-LinePoet · 2026-02-04T10:11:05+00:00

On February 2, 2026, Zevra disclosed insider trading activities, including Board Member McFarlane selling 91,000 shares on the same day. Additionally, other executives also conducted a series of sell transactions on January 30. Zevra is a company focused on rare disease treatments, dedicated to providing transformative therapies to meet patient needs.

K-LinePoet

2026-02-04 10:11:05

Abstract generation in progress

On February 2, 2026, Zevra (ZVRA) disclosed five insider transactions. Director McFarlane Neil F. sold 91,000 shares on February 2, 2026.

【Recent Insider Transactions】

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 2, 2026	Executive	Thompson Rahsaan	January 30, 2026	Sell	4,080	8.83	$36,000
February 2, 2026	Executive	Quartel Adrian W	January 30, 2026	Sell	4,533	8.83	$40,000
February 2, 2026	Executive	Sangiovanni Timothy J.	January 30, 2026	Sell	1,750	8.82	$15,400
February 2, 2026	Director	McFarlane Neil F.	February 2, 2026	Sell	91,000	9.38	$853,400
February 2, 2026	Executive	Schafer Joshua	January 30, 2026	Sell	3,375	8.83	$28,200
January 7, 2026	Shareholder	Clifton R. LaDuane	December 31, 2025	Sell	48,500	8.96	$434,700
October 10, 2025	Director	McFarlane Neil F.	October 10, 2025	Sell	19,500	10.82	$211,900
September 16, 2025	Director	FAVORITO TAMARA A	September 12, 2025	Buy	3,175	7.79	$24,700
September 15, 2025	Director	Shih Alvin	September 12, 2025	Buy	20,000	7.89	$157,800
August 20, 2025	Director	Bode John B	August 19, 2025	Buy	5,000	9.17	$45,800

【Company Information】

Zevra Therapeutics, Inc. was incorporated in October 2006 in Iowa and restructured in Delaware in May 2014. The company is a rare disease company that combines science, data, and patient needs to create transformative therapies for diseases with limited or no treatment options. The company’s mission is to bring life-changing therapies to people with rare diseases. With a unique, data-driven development and commercialization strategy, the company is overcoming complex drug development challenges to provide new treatments for the rare disease community. The company has a diversified portfolio of products and candidates, including preclinical development programs, clinical-stage pipelines, and commercial-stage assets. The team has expertise and a proven track record of advancing promising therapies facing complex clinical and regulatory challenges by balancing science and data with patient needs.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.